Avacta Group plc has announced the appointment of Peel Hunt LLP as Joint Broker alongside Stifel Nicolaus Europe, which acts as Broker and Nomad to the Company. Avacta is a life sciences company focused on developing innovative oncology drugs and diagnostics. The company operates through two divisions, Diagnostics and Therapeutics, with the aim of improving healthcare, fitness, and well-being. Avacta's Therapeutics Division is building a pipeline of novel Affimer immunotherapies and pre|CISION tumour-targeted chemotherapies to address the lack of durable response and reduce systemic toxicities experienced by patients with cancer. The company's lead programme, AVA6000, is a pre|CISION tumour-targeted form of the chemotherapy doxorubicin, currently in Phase I clinical trials. The Affimer platform is an alternative to antibodies, designed to overcome the drawbacks of antibodies in the immuno-diagnostics and immuno-therapeutics markets. The pre|CISION tumour targeting platform modifies chemotherapy to selectively release the active drug in tumour tissue, reducing systemic exposure and improving the safety and therapeutic potential of anti-cancer treatments.